Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160919 | 0.91 | PTGDR2 (0.48) | NAMPTPTGDR2ALDH1A1LMNAMAPT | |
| SCHEMBL2771155 | 0.91 | PTGDR2 (0.57) | PTGDR2ALDH1A1LMNAMAPTPTPN1 | |
| SCHEMBL2773535 | 0.88 | PTGDR2 (0.49) | PTGDR2CA12CA1CA2CA4 | |
| SCHEMBL2773383 | 0.88 | PTGDR2 (0.52) | NAMPTPTGDR2ALDH1A1LMNAMAPT | |
| SCHEMBL2772311 | 0.87 | NAMPT (0.45) | NAMPTPTGDR2CA12CA1CA2 | |
| SCHEMBL2771609 | 0.87 | PTGDR2 (0.45) | NAMPTPTGDR2CA12CA1CA2 | |
| SCHEMBL2773506 | 0.87 | PTGDR2 (0.51) | PTGDR2ALDH1A1LMNAMAPTPTPN1 | |
| SCHEMBL2772807 | 0.86 | PTGDR2 (0.48) | PTGDR2CA12CA1CA2CA4 | |
| SCHEMBL2773337 | 0.86 | PTGDR2 (0.58) | PTGDR2CA12CA1CA2CA4 | |
| SCHEMBL2771950 | 0.86 | PTGDR2 (0.49) | PTGDR2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | claimed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | claimed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | claimed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | HSD17B12, CYP2A13, CYP27A1 | NAMPT 3694/4885PTGDR2 377/4885CA12 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.